Location: Solmed Polyclinic (Zagreb), SB Medico (Rijeka)
Study Drug: Experimental biological therapy is an anti-TNFSF13 antibody that slows down the activity of B lymphocytes, which excessively produce IgA antibodies that are the cause of the disease.
Main Inclusion Criteria: Patients older than 18 years with a diagnosis of IgA nephropathy confirmed by biopsy at any time in the past, who have elevated proteins in a 24-hour urine collection (>1g/24h), but still have satisfactory kidney function (eGFR > 30 ml/min).
Status: Enrolling patients soon
Start of patient enrollment: August 2024
Planned end of patient enrollment: October 2025
